Scientists Gene Hack Mice So Their Livers Produce Their Own Ozempic-Like Drug

Scientists have genetic mice to produce their own-like drugs, perhaps, and perhaps provocative, and may pave the way for humans to do so one day.

In a new study published in the magazine Telecom medicineOsaka University researchers at the University of Osaka succeeded in freeing genes in the release of genes to produce Xinaids, a drug of first -generation diabetes and predecessor to run the direction now such as OzemPIC and Mounjaro.

Using laboratory mice that were obese and diabetes actor-what appears to be, we have to notice, sad and wonderful-researchers used a genetic editing method based on Krisper to add a gene to the rodent liver cells that direct them to how to make Xinide. Soon after, Osaka researchers discovered the medicine in rodent blood, and they continued to find it for up to 28 weeks, as the genetic modified mice show “less food and gained less than their non -editors, and a press statement on the study explained.

This is not the first time that researchers have enjoyed live things with genes in the creation of peptide -1 receptors/1 (GLP -1), a group of medications to which the Ozambi belongs, which is believed to mimic the stomach feeling of fullness. Once again in 2017, researchers from the human skin cells and mice released by genes at the University of Chicago to produce GLP-1, and then vaccinated them on host animals that then showed an increase in insulin secretion and weight gain. Recently, student scientists at Ottawa University in Canada deceived the cousin of tobacco in producing a similar boat.

Everything is assembled together, which is an interesting guide to the concept of detailed genetic treatments that can help the body produce its own drugs – a radical exit from the current model of pharmaceutical and medical industries.

“We hope that our design for genetic therapy will be applied once to many cases that do not contain accurate genetic causes,” explained Keiichiro Suzuki, the great author of the study, in the press statement.

Still, as Gizmodo Notes, not all GLP-1 are created equally. It was taken twice a day orally, as the original formula of oxygen has made the least period of poultry, and although the extended release version was eventually manufactured and sold, both of them have been linked since then due to the long-known risk of pancreatitis-although they were fair, but the Ozambek had been linked in the same condition.

Although it is unclear whether Osaka researchers are planning to try a compound closer to the semules, the Fractyl Health company, which works in the field of biical drugs, is also working on treating genes that train the body to create its GLP-1S. Earlier this year, the company started the process of approving human experiences in Europe, which will start next year if accepted by health organizers.

It is worth noting that any of these mice studies took the GLP-1 elephant in the room: that these medications, regardless of the fine formula, carry a growing risk of pancreatitis and other problems of the digestive system. You can produce them In the live body It leads to lower side effects? It seems too early to know – but we will watch.

More about GLP-1 research: Human experiences on GLP-1 seem very promising